FASN and neoplasm: Preclinical studies have confirmed that combining FASN inhibitors with anti-PD-L1 antibodies significantly suppresses tumor growth [16], while SCD1 inhibition not only enhances CD8 T cell infiltration but may also improve response to PD-1 blockade therapy [17].